



Great
Debates
& Updates

Hematologic Malignancies



Where Debate
& Discussion
Translate
to Treatment

NEW!
3 locations for 2020:

March 6-7
Los Angeles, CA


July 17-18
New York, NY

August 28-29
Chicago, IL

Save \$50 on
registration | Use code
GDUHEME

hemeoncologydebates.com

AN **IMEDEX** EVENT |
AN HMP COMPANY



Interested in Exhibiting?

This conference series offers several support opportunities that are designed to increase your company's recognition and showcase your products and services to this audience of oncology professionals.

678.242.0719 | exhibits@imedex.com

Compelling
Arguments.
Practical
Takeaways.
Engaging
Discussions.

Part of the



Oncology
Learning Network

oncnet.com

The Great Debates & Updates in Hematologic Malignancies conference is best known for its unique debate-style format. Thought leaders from the nation's leading cancer institutes meet onstage to dive into the most controversial topics shaking up the field of hematologic malignancies.

This one-of-a-kind hematology conference provides a substantial curriculum covering the broad continuum of:

- Multiple Myeloma
- Acute Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- “Not-So-Benign” Hematology
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasms
- Lymphoproliferative Diseases

MEETING CHAIRS

New Chair for 2020



Jessica K. Altman, MD

Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL



John P. Leonard, MD

Center for Lymphoma and Myeloma
Weill Cornell Medicine
New York, New York



Joseph R. Mikhael, MD, MEd, FRCPC

City of Hope Cancer Center
Translational Genomics Research Center
Phoenix, Arizona

ENDORSEMENTS

The following organizations endorse this conference:



SCIENTIFIC AGENDA

Day One

8:00 AM	Session I: Plasma Cell Disorders I
10:05 AM	Break
10:25 AM	Session II: Plasma Cell Disorders II
11:50 AM	Lunch
1:20 PM	Session III: Chronic Lymphocytic Leukemia
3:05 PM	Break
3:35 PM	Session IV: Acute Myelogenous Leukemia (AML)/Acute Lymphoblastic Leukemia (ALL)
5:35 PM	Adjourn

Day Two

8:15 AM	Session V: Lymphoma I
10:00 AM	Break
10:20 AM	Session VI: Lymphoma II
11:45 AM	Lunch
1:15 PM	Session VII: Chronic Myeloid Leukemia (CML)
3:00 PM	Break
3:20 PM	Session VIII: Myeloproliferative Neoplasms (MPN)
4:10 PM	Adjourn

Agenda is subject to change. Please visit the website for full program details.

2020 Faculty

Jessica K. Altman, MD**CHAIR**

Robert H. Lurie Comprehensive Cancer Center
Northwestern University
New York, New York

John P. Leonard, MD**CHAIR**

Center for Lymphoma and Myeloma
Weill Cornell Medicine
New York, New York

Joseph R. Mikhael, MD, Med, FRCPC**CHAIR**

City of Hope Cancer Center
Translational Genomics Research Institute
Phoenix, Arizona

Jorge E. Cortes, MD**CONTENT ADVISOR**

Georgia Cancer Center
Augusta, Georgia

Jacqueline C. Barrientos, MD, MS

Donald and Barbara Zucker School of Medicine
Hofstra/Northwell
New Hyde Park, New York

Andrew J. Cowan, MD

Fred Hutchinson Cancer Research Center
Seattle, Washington

Angela Dispenzieri, MD

Mayo Clinic
Rochester, Minnesota

Matthew J. Frigault, MD

Massachusetts General Hospital
Boston, Massachusetts

Richard R. Furman, MD

New York Presbyterian Hospital
Weill Cornell Medicine
New York, New York

Mehdi Hamadani, MD

Cancer Center – Froedtert Hospital
Milwaukee, Wisconsin

Elias J. Jabbour, MD

MD Anderson Cancer Center
Houston, Texas

Amrita Krishnan, MD

City of Hope Comprehensive Cancer Center
Duarte, California

Shaji K. Kumar, MD

Mayo Clinic
Rochester, Minnesota

John O. Mascarenhas, MD

Mount Sinai Hospital
New York, New York

Kami Maddocks, MD

The Ohio State University
Columbus, Ohio

Naveen Pemmaraju, MD

MD Anderson Cancer Center
Houston, Texas

Jerald P. Radich, MD

Fred Hutchinson Cancer Research Center
Seattle, Washington

Ashley E. Rosko, MD

The Ohio State University Comprehensive
Cancer Center
Columbus, Ohio

Keith Stewart, MB, ChB

Mayo Clinic
Phoenix, Arizona

Richard M. Stone, MD

Dana-Farber Cancer Institute
Boston, Massachusetts



**Faculty will vary across all locations and may be subject to change. For a current faculty list, please visit the website.*



WHO SHOULD ATTEND

These live educational activities are designed to meet the educational needs of those who are involved and/or interested in the treatment of patients with multiple myeloma, lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.

- Hematologists
- Medical Oncologists
- Physicians
- Physician Assistants
- Physicians-in-Training
- Oncology Nurses
- Pharmacists

GROUP DISCOUNTS

Available for attendees from the same practice!
To get group discounts, contact our registration team at 800.233.0957 or registration@imedex.com.

ACCREDITATION INFORMATION



In support of improving patient care, this activity has been planned and implemented by the North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health-care team.

PHYSICIANS

This activity has been approved for *AMA PRA Category 1 Credit™*.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES

This continuing nursing education activity has been approved to offer continuing contact hours for nurse professionals.

PHARMACY

This live, knowledge-based activity has been approved to offer continuing education units (CEUs) for pharmacists.

WHO SHOULD ATTEND

These live educational activities are designed to meet the educational needs of U.S. hematologists, medical oncologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with multiple myeloma, lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.

OBJECTIVES

Upon successful completion of these educational activities, participants should be able to:

- Interpret pertinent clinical trial data for standard of care and novel management strategies for hematologic malignancies and benign hematologic disorders
- Assess how integration of relevant clinical trial data into clinical practice has the potential to enhance outcomes in patients with hematologic malignancies and benign hematologic disorders
- Formulate evidence-based strategies for the management of hematologic malignancies and benign hematologic disorders that take into consideration patient risk factors, cost, disease stage, and prior therapeutic regimens

More Locations, Education, and Value.



Los Angeles, CA

Marriott Marina Del Rey

Special Discounted Rate

\$239*

Booking Deadline

1/23/20



New York, NY


Crowne Plaza Times Square
Manhattan

Special Discounted Rate

\$259*

Booking Deadline

6/15/20



Chicago, IL

Hyatt Centric Chicago
Magnificent Mile

Special Discounted Rate

\$179*

Booking Deadline

7/30/20

*Rates are for single occupancy and do not include applicable taxes or fees. See website for additional information.

REGISTRATION RATES	EARLY	REGULAR
Physician/PhD/PharmD	\$279	\$329
PA/NP	\$169	\$199
Nurse/Student/ Resident/Fellow	\$89	\$99
Industry	\$549	\$549

EARLY
REGISTRATION
DEADLINES:

Los Angeles, CA
1/31/20

New York, NY
6/19/20

Chicago, IL
7/31/20

**Enroll in the
Great Debates
& Updates
Value Package
and save by
signing up
for multiple
locations at
once!**

WAYS TO REGISTER

Online: hemeoncologydebates.com

Phone: **800.233.0957**

International: **678.242.0906**

Email: registration@imedex.com

Save \$50 on registration using code **GDUHEME**